Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 1/2020

01-12-2020 | Metronidazole | Research

Risk factors and intestinal microbiota: Clostridioides difficile infection in patients receiving enteral nutrition at Intensive Care Units

Authors: Daosheng Wang, Danfeng Dong, Chen Wang, Yingchao Cui, Cen Jiang, Qi Ni, Tongxuan Su, Guanzheng Wang, Enqiang Mao, Yibing Peng

Published in: Critical Care | Issue 1/2020

Login to get access

Abstract

Background

Clostridioides difficile infection (CDI) is a leading cause of nosocomial diarrhea. Patients receiving enteral nutrition (EN) in the intensive care unit (ICU) are potentially at high risk of CDI. In the present study, we assessed the risk factors and intestinal microbiome of patients to better understand the occurrence and development of CDI.

Methods

Patients were screened for C. difficile every week after starting EN, and their clinical records were collected for risk factor identification. Fecal samples were analyzed using 16S rRNA sequencing to evaluate the intestinal microbiota.

Results

Overall incidence of CDI was 10.7% (18/168 patients). History of cerebral infarction was significantly associated with CDI occurrence (OR, 9.759; 95% CI, 2.140–44.498), and treatment with metronidazole was identified to be protective (OR, 0.287; 95% CI, 0.091–0.902). Patients with EN had lower bacterial richness and diversity, accompanied by a remarkable decrease in the abundance of Bacteroides, Prevotella_9, Ruminococcaceae, and Lachnospiraceae. Of these patients, acquisition of C. difficile resulted in a transient increase in microbial diversity, along with consistent alterations in the proportion of some bacterial taxa, especially Ruminococcaceae and Lachnospiraceae. Upon initiation of EN, patients who were positive for C. difficile later showed an enhanced load of Bacteroides, which was negatively correlated with the abundance of C. difficile when CDI developed.

Conclusion

ICU patients receiving EN have a high prevalence of CDI and a fragile intestinal microbial environment. History of cerebral infarction and prior treatment with metronidazole are considered as vital risk and protective factors, respectively. We propose that the emergence of CDI could cause a protective alteration of the intestinal microbiota. Additionally, Bacteroides loads seem to be closely related to the occurrence and development of CDI.
Appendix
Available only for authorised users
Literature
1.
2.
Lim SC, Knight DR, Riley TV. Clostridium difficile and One Health. Clin Microbiol Infect. 2020;26(7):857–863.
3.
Kuy S, et al. Increasing incidence of and increased mortality associated with Clostridium difficile-associated megacolon. JAMA Surg. 2016;151(1):85–6.PubMedCrossRef
4.
Samarkos M, Mastrogianni E, Kampouropoulou O. The role of gut microbiota in Clostridium difficile infection. Eur J Intern Med. 2018;50:28–32.PubMedCrossRef
5.
Dubberke ER, et al. Clostridium difficile--associated disease in a setting of endemicity: identification of novel risk factors. Clin Infect Dis. 2007;45(12):1543–9.PubMedCrossRef
6.
Bliss DZ, et al. Acquisition of Clostridium difficile and Clostridium difficile-associated diarrhea in hospitalized patients receiving tube feeding. Ann Intern Med. 1998;129(12):1012–9.PubMedCrossRef
7.
Balsells E, et al. Global burden of infections: a systematic review and meta-analysis. J Glob Health. 2019;9(1):010407.PubMedCrossRef
8.
Barletta JF, Sclar DA. Proton pump inhibitors increase the risk for hospital-acquired Clostridium difficile infection in critically ill patients. Crit Care. 2014;18(6):714.PubMedPubMedCentralCrossRef
9.
O'Keefe SJ. Tube feeding, the microbiota, and Clostridium difficile infection. World J Gastroenterol. 2010;16(2):139–42.
10.
Cui, Y., et al., Risk factors for Clostridioides difficile infection and colonization among patients admitted to an intensive care unit in Shanghai, China, BMC Infect Dis, 2019. 19(1): p. 961.
11.
12.
13.
DDebast SB, Bauer MP, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2014;20(Suppl 2):1–26.
14.
15.
16.
Lucado J, Gould C, Elixhauser A. Clostridium difficile infections (CDI) in hospital stays, 2009: statistical brief# 124; 2006.
17.
Manthey CF, et al. Initial therapy affects duration of diarrhoea in critically ill patients with Clostridioides difficile infection (CDI). Crit Care. 2019;23(1):399.
18.
Wang W, et al. The characteristics analysis of intestinal microecology on cerebral infarction patients and its correlation with apolipoprotein E. Medicine (Baltimore). 2018;97(41):e12805.CrossRef
19.
Guh AY, et al. Risk factors for community-associated Clostridium difficile infection in adults: a case-control study. Open Forum Infect Dis. 2017;4(4):ofx171.PubMedPubMedCentralCrossRef
20.
Teasley DG, et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet (London). 1983;2(8358):1043–6.CrossRef
21.
Whelan K, Schneider SM. Mechanisms, prevention, and management of diarrhea in enteral nutrition. Curr Opin Gastroenterol. 2011;27(2):152–9.PubMedCrossRef
22.
Bäckhed F, et al. Host-bacterial mutualism in the human intestine. Science (New York). 2005;307(5717):1915–20.CrossRef
23.
24.
Atarashi K, et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature. 2013;500(7461):232–6.CrossRefPubMed
25.
Lee YJ, et al. Protective factors in the intestinal microbiome against Clostridium difficile infection in recipients of allogeneic hematopoietic stem cell transplantation. J Infect Dis. 2017;215(7):1117–23.PubMedPubMedCentralCrossRef
26.
Freedberg DE, et al. Pathogen colonization of the gastrointestinal microbiome at intensive care unit admission and risk for subsequent death or infection. Intensive Care Med. 2018;44(8):1203–11.PubMedPubMedCentralCrossRef
27.
Zhang L, et al. Insight into alteration of gut microbiota in Clostridium difficile infection and asymptomatic C. difficile colonization. Anaerobe. 2015;34:1–7.PubMedCrossRef
28.
Schubert AM, et al. Microbiome data distinguish patients with Clostridium difficile infection and non-C. difficile-associated diarrhea from healthy controls. mBio. 2014;5(3):e01021–14.PubMedPubMedCentralCrossRef
29.
Gu S, et al. Identification of key taxa that favor intestinal colonization of Clostridium difficile in an adult Chinese population. Microbes Infect. 2016;18(1):30–8.PubMedCrossRef
30.
Antharam VC, et al. Intestinal dysbiosis and depletion of butyrogenic bacteria in Clostridium difficile infection and nosocomial diarrhea. J Clin Microbiol. 2013;51(9):2884–92.PubMedPubMedCentralCrossRef
31.
Crobach MJT, et al. Understanding Clostridium difficile Colonization. Clin Microbiol Rev. 2018;31(2):e00021–17.
32.
Morrison DJ, Preston T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes. 2016;7(3):189–200.PubMedPubMedCentralCrossRef
33.
Buffie CG, et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature. 2015;517(7533):205–8.CrossRefPubMed
34.
Vincent C, et al. Bloom and bust: intestinal microbiota dynamics in response to hospital exposures and Clostridium difficile colonization or infection. Microbiome. 2016;4:12.PubMedPubMedCentralCrossRef
35.
36.
Sangster W, et al. Bacterial and Fungal Microbiota Changes Distinguish C. difficile Infection from Other Forms of Diarrhea: Results of a Prospective Inpatient Study. Front Microbiol. 2016;7:789.
37.
Deng H, et al. Bacteroides fragilis prevents Clostridium difficile infection in a mouse model by restoring gut barrier and microbiome regulation. Front Microbiol. 2018;9:2976.PubMedPubMedCentralCrossRef
38.
Mullish BH, et al. Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent infection. Gut. 2019;68(10):1791–800.PubMedCrossRef
39.
Ferreyra JA, et al. Gut microbiota-produced succinate promotes C. difficile infection after antibiotic treatment or motility disturbance. Cell Host Microbe. 2014;16(6):770–7.PubMedPubMedCentralCrossRef
40.
Metadata
Title
Risk factors and intestinal microbiota: Clostridioides difficile infection in patients receiving enteral nutrition at Intensive Care Units
Authors
Daosheng Wang
Danfeng Dong
Chen Wang
Yingchao Cui
Cen Jiang
Qi Ni
Tongxuan Su
Guanzheng Wang
Enqiang Mao
Yibing Peng
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Critical Care / Issue 1/2020
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/s13054-020-03119-7

Other articles of this Issue 1/2020

Critical Care 1/2020 Go to the issue

Research

Effect of antiviral therapy on the outcomes of mechanically ventilated patients with herpes simplex virus detected in the respiratory tract: a systematic review and meta-analysis

Research

Inpatient hospital performance is associated with post-discharge sepsis mortality

Letter

A new clinical trial to test high-dose vitamin C in patients with COVID-19

Letter

Assessment of pulmonary surfactant in COVID-19 patients

Editorial

Interfacility helicopter transfers for critically ill patients: always the right choice?

Research

Prediction of hypotension events with physiologic vital sign signatures in the intensive care unit